There are concerns that pneumococcal conjugate vaccines (PCV) in sub-Saharan Africa sub-optimally interrupt vaccine-serotype (VT) carriage and transmission, thus limiting vaccine-induced direct and indirect protection. We assessed carriage in vaccinated children and unvaccinated populations targeted for indirect protection, between 4 and 7 years after Malawi's November 2011 introduction of PCV13 using a 3+0 schedule.
BACKGROUND
Streptococcus pneumoniae is estimated to be responsible for over 500 000 deaths every year in children aged 1 to 59 months worldwide, with the highest burden among African children. 1 S. pneumoniae has over 90 immunological serotypes and is a common coloniser of the human nasopharynx, particularly in young children, resource-poor and HIV-affected populations. 1 Although most carriers are asymptomatic, pneumococcal colonisation is a necessary prerequisite for transmission and the development of pneumonia, meningitis, and bacteraemia. 2 In Europe and North America, routine infant administration of pneumococcal conjugate vaccine (PCV) has rapidly reduced vaccine-serotype (VT) invasive pneumococcal disease (IPD) and carriage. [3] [4] [5] [6] Importantly, this has occurred in vaccinated and unvaccinated age groups. Thus, indirect protection resulting from a reduction in carriage and transmission amplifies PCV impact and cost-effectiveness. 7 Pneumococcal epidemiology in sub-Saharan Africa is characterised by high rates of carriage and transmission, differing markedly from high-income settings. 8, 9 Carriage studies pre-dating PCV introduction in Kenya, 8 Mozambique, 10 Malawi, 11 The Gambia, 12 and South Africa 13 , for example, reported VT carriage prevalences ranging from 49.7% to 28.2% in under 5s, with colonisation occurring rapidly early in life. 14 Vaccine trials and post-routine-introduction studies in Africa have demonstrated substantial direct effects of PCV against IPD, pneumonia, and all-cause mortality among young children. [15] [16] [17] [18] Although Kenya, 19 The Gambia, 18 Mozambique 20 , and South Africa 21 have reported VT carriage reductions, residual carriage prevalences are still higher than in industrialised countries. [22] [23] [24] In addition, there is evidence of rapid onset of NVT replacement in the region. 25 Thus, it is uncertain whether PCV introduction in sub-Saharan Africa will achieve the sustained control of pneumococcal carriage necessary to effectively interrupt transmission and so disease. This is of particular concern in many sub-Saharan African countries where the 3+0 schedule has been implemented into infant expanded programmes on immunisation (EPI). 26 In November 2011, Malawi (previously PCV-naïve) introduced 13-valent PCV as part of the national EPI using a 3+0 schedule (6, 10 and 14 weeks of age). A three-dose catch-up vaccination campaign included infants <1 year of age. Field studies among age-eligible children have reported a high PCV13 uptake of 90-95%, 27, 28 even higher than the 83% previously reported by WHO/UNICEF. 29 In 2011, Malawi adopted Option B+, whereby all HIV-positive pregnant or breastfeeding women commence lifelong full ART regardless of clinical or immunological stage, dramatically reducing mother-to-child-transmission. 30 We hypothesised that despite evidence of PCV13 impact on IPD and pneumonia in Malawi, 31, 32 there would be persistent VT carriage and that this would maintain transmission in both childhood and adult reservoirs. We have investigated this among PCV13-vaccinated children (in whom vaccine-induced immunity wanes after the first year of life 33 ); children too old to have received PCV13; and HIV-infected adults on antiretroviral therapy (ART) who do not routinely receive pneumococcal vaccination (previously demonstrated to have a high carriage prevalence 34, 35 ).
METHODS

Study Design
This was a prospective cross-sectional observational study using stratified random sampling to measure pneumococcal nasopharyngeal carriage in Blantyre, Malawi. Sampling consisted of a time series profile from twice-annual surveys over 3.5 years.
Study population and recruitment
Blantyre is located in Southern Malawi with an urban population of approximately 1·3 million.
Recruitment included four groups: i) healthy infants 4-8 weeks old prior to first dose of PCV, recruited from vaccination centres using systematic sampling; ii) randomly sampled healthy children 18 weeks-7 years old who received PCV as part of EPI or the catch-up campaign, recruited from households and public schools; iii) randomly sampled healthy children 3-10 years old who were age-ineligible (born on or before 11 November 2010 and therefore too old) to receive PCV as part of EPI or the catch-up campaign), recruited from households and public schools; and iv) HIV-infected adults 18-40 years old and on ART, recruited from Blantyre's Queen Elizabeth Central Hospital ART Clinic using systematic sampling. Individuals were not purposely resampled but were eligible if randomly re-selected in subsequent surveys.
Recruitment of infants
Site selection
Households, schools and vaccination centres were selected from within three nonadministrative zones representative of urban Blantyre's socioeconomic spectrum in mediumto high-density townships. These zones were further divided into clusters, allowing for approximately 25 000 adults per zone and 1 200 adults per cluster. Clusters were not purposely resampled but eligible if randomly selected in subsequent surveys. Within each cluster, after randomly choosing a first house, teams moved systematically, recruiting one eligible child per household until the required number of children were recruited from each cluster. Individual school-goers were randomly selected from school registers, and letters sent home inviting parents or legal guardians to travel to the school to discuss the study and consider consenting to their child's participation.
Determining PCV vaccination status
A child was considered "PCV-vaccinated" if s/he had received at least one dose of PCV prior to screening. Vaccination status and inclusion/exclusion criteria were further assessed from subject-held medical records (known as Health Passports). If a child was reported by the parent/guardian to be PCV-vaccinated but no health passport was available, a questionnaire was applied. The questionnaire was developed by identifying, among a subset of 60 participants, four questions most commonly answered correctly by parents/guardians of children with proof of PCV vaccination. The questions included child's age when vaccinated, vaccine type (oral or injectable), anatomical site of vaccination, and which other (if any) vaccines were received at the time of PCV vaccination. If the child was PCV age-eligible and answered all four questions correctly, the child was recruited as "PCV-vaccinated."
Sample size
The sample size strategy was a pragmatic approach to allow for adequate precision of the carriage prevalence estimates. Using VT carriage as the primary endpoint, the sample size was calculated based on the precision of the prevalence estimation, assuming an infinite sampling population. Among children 3-7 years old (vaccinated), an absolute VT prevalence up to 10% was expected, with a sample of 300/survey providing a 95% confidence interval (CI) of 6·6-13·4%. Among children 3-10 years old (unvaccinated) and HIV-infected adults, an absolute VT prevalence of 20% was expected, with a sample of 200/survey providing a 95% CI of 14·5-25·5%.
Nasopharyngeal swab collection
A nasopharyngeal swab (NPS) was collected from each participant using a nylon flocked swab (FLOQSwabs TM , Copan Diagnostics, Murrieta, CA, USA) and then placed into 1·5mL skim milk-tryptone-glucose-glycerol (STGG) medium and processed at the Malawi-Liverpool-Wellcome Trust (MLW) laboratory in Blantyre, according to WHO recommendations. 36 Samples were frozen on the same day at −80°C.
Pneumococcal identification and latex serotyping
After being thawed and vortexed, 30 µL NPS-STGG was plated on gentamicin-sheep blood agar (SBG; 7% sheep blood agar, 5 µl gentamicin/mL) and incubated overnight at 37°C in 5% CO 2 . Plates showing no S. pneumoniae growth were incubated overnight a second time before being reported as negative. S. pneumoniae was identified by colony morphology and optochin disc (Oxoid, Basingstoke, UK) susceptibility. The bile solubility test was used on isolates with no or intermediate (zone diameter <14mm) optochin susceptibility. A single colony of confirmed pneumococcus was selected and grown on a new SBG plate as before.
Growth from this second plate was used for serotyping by latex agglutination (ImmuLex™ 7-10-13-valent Pneumotest; Statens Serum Institute, Denmark). This kit allows for differential identification of each PCV13 VT but not for differential identification of NVT serotypes; NVT and non-typeable isolates were therefore reported as NVT. Samples were batch tested on a weekly basis, blinded to the sample source. Latex serotyping results showed good concordance with whole genome sequence and DNA microarray serotyping. 37
Statistical analysis
Participant demographic characteristics were summarised using means, standard deviations, medians, and ranges for continuous variables and frequency distributions for categorical variables. Non-ordinal categorical variables were assessed as indicators.
Carriage prevalence ratios (PR) were calculated over the study duration by log-binomial regression using months (30.4 days) between study start and participant recruitment, coded as a single time variable, allowing an estimate of prevalence ratio per month. Potential confounders were identified by testing the association between variables and included in the multivariable models when p<0.1. Adjusted prevalence ratios (aPR) were calculated using log-binomial regression. Confidence intervals are binomial exact. Statistical significance was inferred from two-sided p<0·05. Statistical analyses were completed using Stata 13.1 (StataCorp, College Station, TX, USA).
Non-linear regression analysis for VT carriage decay rate and half-life
To better understand the rate at which VT and NVT carriage prevalence was decreasing, we developed a non-linear model to describe the variation in probability of VT or NVT carriage with age, adjusted for age at recruitment. The model is fitted using carriage data from 
Demographics and vaccination history
The surveyed groups had similar demographics (Table 1) Among the 3630 PCV-vaccinated children recruited and providing an NPS, 1209 (33·3%) had documented (health passport) vaccination status with dates of vaccination; ranging from 86.5% among the youngest vaccinated age group (18 weeks-1-year-old) to 25.7% among the oldest vaccinated age group (3-7 years old). Among those with health passports confirming dates of vaccination, the median (IQR) age at first, second, and third dose of PCV were 6·3 (3·2), 11·2 (5·0), and 16·4 (8·1) weeks, respectively; 1143 (94·5%) received three doses PCV, 24 (2.0%) only two doses and 42 (3·5%) only one dose. 1 The gender distribution among adults recruited from ART Clinic is representative of the gender distribution among those attending the clinic. 
Pneumococcal carriage
Among children 4-8 weeks (prior to first dose PCV) aggregated (surveys 5-7) VT and NVT carriage prevalence were respectively, 8·4% (95% CI 5·7-11.8) and 33·8% (95% CI 28·8-39·1). There was a 25·2% relative reduction in VT carriage, from 10·7% (95% CI 6·3-17·7) in survey 5 to 8·7% (4·4-16·5) in survey 7. (Figure 2 ; Table 2 ) When adjusted for age at recruitment, the adjusted prevalence ratio (aPR) over the 3 surveys was 0·974 (95% CI 0·902-1·052) p=0·506. Supplement 3 shows the aPR for VT carriage, stratified by individual survey within each age group. There was a 51·9% relative increase in NVT carriage, from 32·2% (24·5-41·1) in survey 5 to 48·9% (38·8-59·1) in survey 7. The aPR was 1·037 (1·002-1·073), p=0·038.
Among PCV-vaccinated children 18 weeks-1-year-old ( Figure 2 ; Table 2 ), aggregated (surveys 4-7) VT and NVT carriage prevalence were respectively, 17·1% (95% CI 14·2-20·5) and 62·7% (95% CI 58·6-66·6). There was a 21·1% relative reduction in VT carriage, from 19·0% (95% CI 13·5-26·0) to 15·0% (9·7-22·3); aPR 0·988 (95% CI 0·962-1·014), p=0·351. There was a 13·8% relative increase in NVT carriage, from 58·1% (50·2-65·8) to 66·1% (57·4-73·9); aPR: 1·003 (0·994-1·012), p=0·493.
Among children 2 years old (PCV-vaccinated), aggregated (surveys 4-7) VT and NVT carriage prevalence were respectively, 18·4% (95% CI 15·3-22·1) and 58·5% (95% CI 54·1-62·8). There was a 30·7% relative reduction in VT carriage, from 21·8% (15·3-30·0) to 15·1% (9·8-22·5); aPR: 0·980 (0·955-1·006), p=0·136. There was a 6·7% relative increase in NVT carriage, from 56·5% (47·6-64·9) to 60·3% (51·5-68·5); aPR: 0·999 (0·988-1·009), p=0·802. (Figure 2 ; Table 2) Among children 3-7 years (PCV-vaccinated), aggregated (surveys 1-7) VT and NVT carriage prevalence were respectively, 18·0% (95% CI 16·5-19·5) and 56·2% (95% CI 54·2-58·1). There was a 16·1% relative reduction in VT carriage, from 19·9% (15·7-25·0) to 16·7% (13·2-20·8); aPR: 0·993 (0·986-0·999), p=0·046. (Figure 2 ; Table 2 ) A sensitivity analysis among the PCV-vaccinated age groups showed neither the overall VT prevalence nor the VT distribution changed significantly when limiting these analyses to children i) who received only one, only two, or all three doses PCV; ii) with document-confirmed PCV vaccination or iii) who adhered to the vaccination schedule to within 2 weeks of each scheduled dose (data not shown). There was a 4·5% relative reduction in NVT carriage, from 64·3% (95% CI 58·6-69·7) to 61·4% (95% CI 56·4-66·2); aPR: 0·999 (0·996-0·1.002), Among PCV-unvaccinated children 3-10 years old, aggregated (surveys 1-7) VT and NVT carriage prevalence were respectively, 18·2% (95% CI 16·2-20·3) and 38·5% (95% CI 35·9-41·0). There was a 44·7% relative reduction in VT carriage, from 27·5% (22·3-33·3) to 15·2% (10·8-21·0); aPR: 0·989 (0·979-0·999), p=0·029. There was a 3·2% relative increase in NVT carriage, from 40·8% (34·9-46·9) to 42·1% (35·4-49·2); aPR: 1·005 (0·999-1·010), p=0·101. (Figure 2 ; Table 3) Among HIV-infected adults on ART, aggregated (surveys 1-7) VT and NVT carriage prevalence were respectively, 12·3% (95% CI 10·8-13·9) and 28·1% (95% CI 26·0-30·2).
There was a 41·4% relative reduction in VT carriage, from 15·2% (10·8-20·9) to 8·9% (5·7-13·7); aPR: 0·983 (0·973-0·994), p=0·002. There was an increase 22·7% relative increase in NVT carriage, from 24·2% (18·8-30·7) to 29·7% (23·8-36·4); aPR: 0·997 (CI 0·991-1·004), p=0·392. (Figure 2 ; Table 3) Although all 13 VTs were identified in each of the three older (3 years-40 years old) study groups, with serotype 3 the predominant VT in each, serotype carriage dynamics were more heterogenous among those <3 years old. (Figure 3 ; Supplement 2). Serotype 1, a common cause of IPD in Africa, 38, 39 contributed 3.0% to the all-ages VT carriage prevalence. cPR=crude prevalence ratio. aPR= adjusted prevalence ratio (adjusted for age at recruitment). CI=confidence interval. VT=vaccine serotype. NVT=nonvaccine serotype. n=total number recruited. § There was no recruitment for these age groups during the specified surveys ¥ Carriage prevalence ratios (PR) were calculated over the study duration by log-binomial regression using months (30·4 days) between study start and participant recruitment, coded as a single time variable, allowing an estimate of prevalence ratio per month. cPR=crude prevalence ratio. aPR= adjusted prevalence ratio (adjusted for age at recruitment). CI=confidence interval. VT=vaccine serotype. NVT=nonvaccine serotype. n=total number recruited. § There was no recruitment for these age groups during the specified surveys ¥ Carriage prevalence ratios (PR) were calculated over the study duration by log-binomial regression using months (30·4 days) between study start and participant recruitment, coded as a single time variable, allowing an estimate of prevalence ratio per month.
Probability of VT and NVT carriage with age and estimated carriage half-life
Using non-linear regression analysis to investigate the risk of VT carriage by age among children 3·6-10 years old, the probability of VT carriage was found to decline with age ( Figure 4 ). With carriage data censored at a minimum of 3·6 years of age, the populationaveraged effect of not receiving the vaccination more than doubled the probability of VT carriage, β =2·15 (95% CI 1·47-2·83) ( Assessment of the goodness-of-fit indicates a good fit, with no discernible relationship between the residual and the predicted values and the range of residuals compatible with the theoretical mean and the standard deviations of 0 and 1, respectively (Supplement 1, Figure 3 ).
DISCUSSION
In this community-based assessment of pneumococcal carriage we surveyed potential reservoir populations after the introduction of routine PCV13 in Malawi. Over the 3.5-year study period, we found only a modest relative decline in VT carriage among recently vaccinated children 18 weeks to 1 year old (21%), vaccinated children 2 years old (31%) and vaccinated children 3-7 years old (16%). All 13 VTs were isolated, despite high vaccine uptake and good schedule adherence. There was only a modest increase in NVT carriage.
The 18% residual aggregated VT carriage prevalence among PCV-vaccinated children was consistent with the 16.5% previously reported among PCV-vaccinated children 1-4 years old in northern Malawi, 3.5 years after PCV13 introduction. 11 Though these reported residual VT carriage prevalences were lower than that observed in northern Malawi before vaccine introduction (28%), 11 they did not reach the substantially lower levels rapidly achieved in high-income low-carriage prevalence settings (<5%) associated with control of carriage and transmission. [22] [23] [24] VT carriage dynamics did not conform to a simple exponential distribution, with slightly higher VT carriage prevalence among PCV-vaccinated children under 4 years of age than older vaccinated children. The trend of reduced VT carriage was also evident in older unvaccinated children, suggesting that the effect is age-driven and not simply vaccine dependent (Supplement 1). This underlines the complex relationship in the first few years of life between VT carriage and the impact of waning vaccine-induced mucosal immunity and acquisition of natural immunity. We found a more marked decline in VT carriage among unvaccinated (age-ineligible) children 3-10 years old (45%), and HIV-infected adults on ART (41%). In the light of the recent WHO Technical Expert Consultation Report on Optimization of PCV Impact, 40 these data start to address the paucity of information on the long-term impact of the widely implemented 3+0 vaccine schedules on serotype-specific disease and carriage in this region.
The lower probability of carriage among vaccinated children suggests vaccination does reduce the probability of VT carriage, providing a lower VT carriage setpoint. However, much of that direct vaccine-induced protection occurs quite early, perhaps within the first 6 months of life, and we suggest that thereafter the decline in carriage probability is determined by natural immunity. Indeed, our non-linear statistical analysis shows comparable half-life of VT carriage between PCV-vaccinated and PCV-unvaccinated children beyond the age of 3.6
years. The mechanism underlying the vaccine effect could be prevention of carriage (reduced incidence) or shortening of carriage duration (reduced point prevalence). We further postulate that in older vaccinated and unvaccinated children, the reductions in carriage prevalence are due to the indirect benefits of vaccination augmented by naturally acquired immunity to subcapsular protein antigens. 41, 42 To achieve herd protection in settings with high carriage prevalence, such as Malawi, we need to effectively interrupt person-to-person transmission. In Finland, a microsimulation model suggested a moderate transmission potential of pneumococcal carriage, predicting the elimination of VT carriage among those vaccinated within 5-10 years of PCV introduction, assuming high (90%) vaccine coverage and moderate (50%) vaccine efficacy against acquisition. 43 Thus, vaccine impact predicted by transmission models from low carriage prevalence settings probably does not translate to high carriage prevalence settings. Although it has previously been assumed that PCVs would eliminate VT carriage in mature PCV programmes, 44 our data bring into question the potential for either a sustained direct or indirect effect on carriage using a 3+0 strategy.
In Malawi, the vaccine impact on carriage prevalence has been less than that observed in Kenya, The Gambia and South Africa which have used different vaccination strategies.
Kenya reported a reduction from 34% to 9% VT carriage among PCV-vaccinated children under 5 years of age, 6 years after introduction of 10-valent PCV. 19 The Gambia reported a reduction from 50% to 13% VT carriage among children 2-5 years old, 20 months after introducing the 7-valent PCV. 45 Likewise, a study from South Africa showed reduced PCV13serotype colonisation from 37% to 13% within 1 year of transitioning from PCV7 to PCV13. 46 However, these countries have also not achieved the low carriage prevalences seen in Europe and North America 2 to 3 years post introduction. 3, 47 We propose that a high force of infection (FOI) in settings such as Malawi limits a 3+0 schedule to achieving only a short duration of VT carriage control in infants. While a 2+1 schedule, as deployed in South Africa, may improve colonisation control, this remains unproven in other African settings. Given the likely importance of an early reduction in transmission intensity to maintain a reduced carriage prevalence, a catch-up-campaign with booster doses over a broader age range (i.e.
<5 years of age) may also be required. Although the Global Alliance for Vaccines and Immunization (GAVI) has considerably reduced PCV costs for low-income countries, 48, 49 vaccine impact must be optimised (particularly indirect effects) to achieve financial sustainability. The FOI and determinants of transmission between and within age groups need to be considered, as new approaches to improving vaccine-induced carriage reduction are proposed and tested.
Unlike low-transmission settings, 50 as well as The Gambia 25 and South Africa, 46 we observed a modest increase in NVT carriage among children in Malawi. Given evidence elsewhere of rapid serotype replacement after PCV introduction, it is possible that serotype replacement and redistribution had already occurred before the start of this study, and that as part of a stochastic secular trend, we are now observing an overall decrease in pneumococcal carriage prevalence. There may have also been individual NVT that increased, while other NVT decreased, in prevalence. Though distribution of individual NVT serotypes warrant further analysis, our latex serotyping methods did not allow for identifying individual NVT serotypes. It is also plausible that overall improvement in living conditions (improved nutrition, sanitation and disease control) and health care (antiretroviral roll-out and rotavirus vaccination) have allowed a sustained drop in pneumococcal carriage as a result of improved health, evidenced by falling under 5 mortality in recent years. 51 Either way, the importance of these trends in NVT carriage will become clearer as the trends in NVT invasive disease become available from these different settings.
We have previously shown incomplete pneumococcal protein antigen-specific reconstitution of natural immunity and high levels of pneumococcal colonisation in HIV-infected Malawian adults on ART. 33 We now show that the adult population has not greatly benefitted from indirect protection against carriage following routine infant PVC13 introduction and indeed may represent a reservoir of VT carriage and transmission. Previous studies in Malawi and South Africa have suggested that despite a higher risk of VT pneumococcal colonisation among HIV-infected women, they are still unlikely to be a significant source of transmission to their children. 14, 52 However, in the context of routine infant PCV13 and rapid waning of vaccine-induced immunity, the balance of transmission may now be different. Given the higher risk of IPD, ongoing burden of pneumococcal pneumonia, 53, 54 and the evidence that PCV protects HIV-infected adults from recurrent VT pneumococcal infections, 55 targeted vaccination benefitting this at-risk population may help reduce overall carriage and disease prevalence.
Limitations
This work provides a robust community-based estimate of VT and NVT pneumococcal carriage in Blantyre. The study was conducted over a relatively short timeframe for understanding long-term temporal trends. For this reason, the statistical analysis is limited in its ability to disentangle the effects of calendar time and age-since-vaccination, given the small overlap in ages of vaccinated and unvaccinated children in our data. Although there are pre-vaccine-introduction data from elsewhere in Malawi, there are no equivalent historical carriage data for urban settings in Malawi using the same sampling frame.
However, this does not detract from the finding of high levels of residual VT carriage in these reservoir populations. Finally, given evidence that more sensitive serotyping methods that detect multiple serotype carriage (e.g. DNA microarray) will increase VT carriage estimates, our carriage prevalence data likely underestimate the true residual VT prevalence levels. [56] [57] [58] 
CONCLUSION
Despite success in achieving direct protection of infants against disease, a 3+0 PCV13 schedule in Malawi has not achieved the low universal VT carriage prevalence reported in high-income settings and that is required to control carriage and transmission. We propose that although vaccine-induced immunity reduces the risk of VT carriage in children up to approximately 6 months of age, in the context of a high residual FOI, this impact is limited by rapid waning of vaccine-induced mucosal immunity and pneumococcal recolonisation ( Figure 5 ). Therefore, alternative schedules and vaccine introduction approaches in high pneumococcal carriage, high-disease-burden countries should be revisited through robust evaluation rather than through programmatic change without supporting evidence.
Furthermore, we need to better understand the relative impact of waning vaccine-induced immunity, indirect vaccine protection and naturally-acquired immunity on VT carriage in the two to three years after vaccination. . Older age groups, with data from surveys 1-7 included PCV-vaccinated children 3-7yrs (D), PCV-unvaccinated children 3-10yrs old (E), and HIV-infected adults on ART (F). 95% confidence interval error bars are shown. Prevalence of non-carriers is calculated by 1−(NVT+VT). Refer to Table 2 for VT & NVT prevalence stratified by survey and (adjusted) prevalence ratios; Refer to Appendix 2 for Proportion and frequency of VT carriage attributed to each VT, stratified by study. , with an optimal immunogenic response for vaccineinduced mucosal immunity 4 weeks later (C). Among PCV-vaccinated children, 18-weeks is the approximate vaccine-induced set point, with a rapid decrease in VT prevalence (C-E) until 6 months of age (E). At 6 months of age, there is an increase in risk of VT carriage (E-F), driven by increased force of infection in the context of waning vaccine-induced immunity, the former due partly to increased contact with other young children in the household and community. VT carriage prevalence increases until naturally acquired immunity starts to impact on colonisation (F), reducing pneumococcal carriage prevalence. Among PCV-unvaccinated children, risk of VT carriage continues to increase largely unchecked (B-D) until naturally acquired immunity starts to impact on colonisation (D), reducing pneumococcal carriage prevalence. Among these unvaccinated children, 12 months is the approximate set-point induced by naturally-acquired immunity. Indirect vaccine effects will impact on the height of C-E-F and B-D, as well as the rate of decline in VT carriage prevalence.
